WHIP 180

Drug Profile

WHIP 180

Alternative Names: WHI-P180

Latest Information Update: 24 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wayne Hughes Institute
  • Developer Transition Therapeutics; Wayne Hughes Institute
  • Class Antiallergics; Antihistamines
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Brain cancer; Food hypersensitivity; Urticaria

Most Recent Events

  • 15 Mar 2006 Preclinical trials in Brain cancer in Canada (unspecified route)
  • 15 Sep 1998 Preclinical development for Allergic rhinitis in USA (Unknown route)
  • 15 Sep 1998 Preclinical development for Food allergy in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top